| 07.06.22 | Endo flunks phase 2 frozen shoulder trial; Cerebral bags $40M for epilepsy implant R&D

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

2 jahre vor

Html
Text

Webinar: Improving Patient Outcomes to Ensure Timely Access to Life-Changing and Life-Saving Treatments

Wednesday, July 13, 2022 | 11am ET / 8am PT

In this webinar, you will learn how we are collaborating with our customers to streamline interactions between patients, providers, and manufacturers of specialty drugs, ensure the timely delivery of records, claims, and submissions via a secure portal, and more. Register now.

Today's Rundown

Endo's frozen shoulder plan comes unstuck, with phase 2 flop driving strategy reevaluation Getting Cerebral: VCs bet $40M on epilepsy implant development Zimura 2.0: Iveric taps DelSiTech to develop sustained-release form of retinal disease prospect Avacta's doxorubicin prodrug clears another early safety test ReCode breaks the mold with $120M financing, bringing clutch of Big Pharmas along for ride 'The Top Line' podcast: FDA's coming COVID shot makeover, what's driving new M&A activity, plus this week's headlines

Featured Story

Endo's frozen shoulder plan comes unstuck, with phase 2 flop driving strategy reevaluation

By Nick Paul Taylor

Endo International’s attempt to use ultrasound-guided injection of collagenase clostridium histolyticum to treat frozen shoulder has come unstuck. The drug, the active ingredient in the approved Xiaflex, failed to beat placebo in a phase 2 clinical trial, driving Endo to reevaluate its plans in the indication.

Webinar: The Shift to FSP Outsourcing: Industry Trends and Challenges

Thursday, July 14, 2022 | 2pm ET / 11am PT

This webinar examines key industry challenges that have contributed to the growth of FSP outsourcing. We will also cover observed levels of FSP market size as an increasing percentage of outsourcing, and outline specific benefits offered by FSP solutions. Register Now.

Getting Cerebral: VCs bet $40M on epilepsy implant development

By Nick Paul Taylor

Cerebral Therapeutics has secured cash to get its implanted infusion epilepsy treatment ready for phase 3 development. Lynx1 Capital Management led the series C round, joining with VCs including RA Capital Management and Perceptive Advisors to give Cerebral $40 million to wrap up a midphase study.

Zimura 2.0: Iveric taps DelSiTech to develop sustained-release form of retinal disease prospect

By Nick Paul Taylor

Iveric Bio has struck a deal to switch up the delivery profile of its age-related macular degeneration prospect Zimura. With phase 3 data on the current formulation due soon, the retinal disease biotech has partnered with DelSiTech to develop a sustained-release successor.

Avacta's doxorubicin prodrug clears another early safety test

By Nick Paul Taylor

Avacta has cleared another small hurdle in its race to provide an improved doxorubicin using its delivery platform. The safety data monitoring committee gave the thumbs-up to Avacta after reviewing data from the second dose cohort, clearing the company to step up to the next level.

ReCode breaks the mold with $120M financing, bringing clutch of Big Pharmas along for ride

By Gabrielle Masson

ReCode Therapeutics has stuck to a formula of $80 million funding rounds, but thanks to investments from the venture arms of Bayer and Amgen, the genetic medicine and mRNA biotech is breaking the mold with a $120 million extended series B.

'The Top Line' podcast: FDA's coming COVID shot makeover, what's driving new M&A activity, plus this week's headlines

By Teresa Carey

This week on "The Top Line," we discuss what FDA advisors want added to future COVID vaccine doses—and why. Also, experts predict an uptick in dealmaking, particularly for a few key companies.

Webinar Download: The Faster Path From Pre-Filled Syringe to Auto-Injector

When transitioning from a traditional pre-filled syringe to an auto-injector, it’s important your manufacturing and device partners work together to help get your product to market, faster. Watch this webinar where Ypsomed and Catalent Biologics discuss integrated approaches to do just that. View Now.